Day: January 13, 2026
Regulated Information
January 13, 2026HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT
Under the liquidity agreement entered into between Renault SA and BNP Paribas, the following resources appeared on the liquidity account on December 31, 2025:143,730 shares€ 21,061,685.In the second half of 2025, were carried out:7,239 purchase transactions for 1,585,881 shares and € 54,894,7569,555 sale transactions for 1,571,001 shares and €54,826,677.As a reminder:
1. In the previous half-year report, on June 30, 2025, the following resources appeared on the liquidity account:128,850 shares€ 21,129,764.2. In the first half of 2025, were carried out:9,654 purchase transactions for 2,019,314 shares and €93,437,616
12,415 sale transactions for 1,914,067 shares and €89,088,2223. As of the date of the signature of the liquidity...
National Fuel Schedules First Quarter Fiscal 2026 Earnings Conference Call
Written by Customer Service on . Posted in Public Companies.
WILLIAMSVILLE, N.Y., Jan. 13, 2026 (GLOBE NEWSWIRE) — National Fuel Gas Company (NYSE: NFG) today announced it will release its first quarter fiscal 2026 earnings results on Wednesday, January 28, 2026 after market close.
A conference call to discuss the results will be held on Thursday, January 29, 2026 beginning at 9:00 a.m. ET and will include prepared remarks from the executive team followed by a question and answer session.
All participants must pre-register to join this conference using the Participant Registration link.
A webcast link to the conference call will be provided under the Events Calendar on the NFG Investor Relations website at investor.nationalfuelgas.com.
A replay will be available following the call through the end of the day, Thursday, February 5, 2026. To access the replay, dial 1-866-813-9403 and provide...
Results of additional issuance – RIKB 38 0215 – RIKS 29 0917
Written by Customer Service on . Posted in Public Companies.
As stated in paragraph 6 in General Terms of Auction for Treasury bonds, the Government Debt Management offered the equivalent of 10% of the nominal value sold in the auction 9. January, at the price of accepted bids.Series
RIKB 38 0215
RIKS 29 0917ISIN
IS0000037265
IS0000037711Additional issuance (nominal)
1,171,000,000
224,500,000Settlement date
01/14/2026
01/14/2026Total outstanding (nominal)
61,648,000,000
95,903,798,496
Westland Insurance acquires PV&V Insurance Centre Ltd. / Meester Insurance Centre
Written by Customer Service on . Posted in Mergers And Acquisitions.
Westland Insurance strengthens its Ontario footprint, adding greenhouse insurance expertise to its growing portfolio
Surrey, BC/Territories of the Coast Salish (Kwantlen, Katzie, Semiahmoo, Tsawwassen First Nations), Jan. 13, 2026 (GLOBE NEWSWIRE) — Westland Insurance, one of Canada’s largest insurance brokerages, today announced that it acquired PV&V Insurance Centre Ltd. and Meester Insurance Centre (collectively “PV&V”) effective January 1, 2026. The acquisition of PV&V underscores Westland’s commitment to strengthening its Ontario presence and broadening access to tailored insurance solutions for individuals and businesses across the province.
With operating locations in Burlington and Smithville, PV&V has been proudly serving communities across Southern Ontario and the Niagara region since the 1980’s, including...
Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform
Written by Customer Service on . Posted in Mergers And Acquisitions.
New U.S. intellectual property protections expand use of Minovia’s leading technology in mitochondrial-based therapies for primary mitochondrial and severe renal diseases
HAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Therapy (MAT) platform.
The newly granted patents cover mitochondrial augmentation therapy for primary mitochondrial diseases and mitochondrial augmentation therapy for renal diseases, providing extended protection for Minovia’s core platform...
Glo Fiber Launches 8 Gig Fiber Internet Service
Written by Customer Service on . Posted in Public Companies.
Glo FiberThe Glo Fiber team on the move!EDINBURG, Va., Jan. 13, 2026 (GLOBE NEWSWIRE) — Glo Fiber, powered by Shenandoah Telecommunications Company (Shentel) (Nasdaq: SHEN), has launched symmetrical 8 Gig fiber internet service for residential customers across Virginia, West Virginia, Maryland, Pennsylvania, Delaware, and Ohio. More than 400,000 homes and businesses now have access to Glo Fiber’s 100% fiber optic network and the fastest broadband speeds available in these markets.
“Integrating 8 Gig internet service into our multi-gig product portfolio ensures Glo Fiber continues to lead with the fastest and most reliable internet available in the community,” said Rick Mason, Shentel’s Senior Vice President of Engineering and Operations. “Glo Fiber is building the infrastructure not just for today, but also for the future....
Dimensional Fund Advisors Ltd. : Form 8.3 – RIO TINTO PLC – Ordinary Shares
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.
KEY INFORMATION
(a)
Full name of discloser:
Dimensional Fund Advisors Ltd. in its capacity as investment advisor and on behalf its affiliates who are also investment advisors (”Dimensional”). Dimensional expressly disclaims beneficial ownership of the shares described in this form 8.3.
(b)
Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)
Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree
Rio...
Golden Triangle Ventures Signals Turnaround Momentum as Final Cleanup Nears, Balance Sheet Strengthens, and Core Businesses Accelerate Toward 2026 Expansion
Written by Customer Service on . Posted in Public Companies.
AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) — via IBN —Golden Triangle Ventures (OTC: GTVH), today issued a corporate update signaling a decisive shift into its next phase, as the Company closes in on the final remaining items related to legacy cleanup, strengthens its balance sheet, and accelerates momentum across its core operating businesses.
Over the past several months, Golden Triangle Ventures has taken direct action to address legacy balance sheet and structural matters that previously constrained the Company. Management confirmed that millions of dollars in historical debt have been removed from the balance sheet, materially improving the Company’s financial position and reducing legacy overhang. As a result, only a small number of final cleanup items remain, and the Company is now nearing completion of this phase.
The...
Stellantis Announces 2026 Corporate Calendar
Written by Customer Service on . Posted in Public Companies.
Stellantis Announces 2026 Corporate Calendar
AMSTERDAM, January 13, 2026 – Stellantis N.V. announced today the following corporate calendar for 20261:
February 26, 2026 Full Year 2025 Financial Results
April 30, 2026 Q1 2026 Financial Results
July 30, 2026 Q2 2026 Financial Results
October 28, 2026 Q3 2026 Financial Results
A webcast and conference call hosted by Stellantis are also planned for each of the above dates. Webcasts of the presentations, as well as the related materials, will be accessible under the Investors section of the Stellantis corporate website at www.stellantis.com.
The Annual General Meeting for the approval of Stellantis’ 2025 financial statements is scheduled for April 14, 20262.
The 2026 corporate calendar is available on the corporate website at www.stellantis.com.
#...
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Written by Customer Service on . Posted in Mergers And Acquisitions.
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher
Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist
FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma
Platform targets the core biology of autism, not just symptomatic relief
Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL’s post-transaction share capital
Beyond Air to receive up to $32.5 million in upfront, development and commercial milestone payments
TEL AVIV and BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) — XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTLB.TA) today announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. (NASDAQ:...
